دورية أكاديمية
أعرض في EDS

Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors

التفاصيل البيبلوغرافية
العنوان: Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors
المؤلفون: Jian-Hua Hong, Ming-Chieh Kuo, Yung-Ting Cheng, Yu-Chuan Lu, Chao-Yuan Huang, Shih-Ping Liu, Po-Ming Chow, Kuo-How Huang, Shih-Chieh Jeff Chueh, Chung-Hsin Chen, Yeong-Shiau Pu
المصدر: The World Journal of Men's Health, Vol 42, Iss 3, Pp 587-599 (2024)
بيانات النشر: Korean Society for Sexual Medicine and Andrology, 2024.
سنة النشر: 2024
المجموعة: LCC:Medicine
LCC:Diseases of the genitourinary system. Urology
مصطلحات موضوعية: progression-free survival, prostate neoplasms, prostate-specific antigen, watchful waiting, Medicine, Diseases of the genitourinary system. Urology, RC870-923
الوصف: Purpose: Active surveillance (AS) is one of the management options for patients with low-risk and select intermediate-risk prostate cancer (PC). However, factors predicting disease reclassification and conversion to active treatment from a large population of pure Asian cohorts regarding AS are less evaluated. This study investigated the intermediate-term outcomes of patients with localized PC undergoing AS. Materials and Methods: This cohort study enrolled consecutive men with localized non-high-risk PC diagnosed in Taiwan between June 2012 and Jan 2023. The study endpoints were disease reclassification (either pathological or radiographic progression) and conversion to active treatment. The factors predicting endpoints were evaluated using the Cox proportional hazards model. Results: A total of 405 patients (median age: 67.2 years) were consecutively enrolled and followed up with a median of 64.6 months. Based on the National Comprehensive Cancer Network (NCCN) risk grouping, 70 (17.3%), 164 (40.5%), 140 (34.6%), and 31 (7.7%) patients were classified as very low-risk, low-risk, favorable-intermediate risk, and unfavorable intermediate-risk PC, respectively. The 5-year reclassification rates were 24.8%, 27.0%, 18.6%, and 25.3%, respectively. The 5-year conversion rates were 20.4%, 28.8%, 43.6%, and 37.8%, respectively. A prostate-specific antigen density (PSAD) of ≥0.15 ng/mL2 predicted reclassification (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.17–2.88) and conversion (HR 1.56, 95% CI 1.05–2.31). A maximal percentage of cancer in positive cores (MPCPC) of ≥15% predicted conversion (15% to
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2287-4208
2287-4690
Relation: https://doaj.org/toc/2287-4208; https://doaj.org/toc/2287-4690
DOI: 10.5534/wjmh.230107
URL الوصول: https://doaj.org/article/41d3fd7dae4a4e9e950de04720ad2b31
رقم الأكسشن: edsdoj.41d3fd7dae4a4e9e950de04720ad2b31
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:22874208
22874690
DOI:10.5534/wjmh.230107